{"id":"cicletanine","rwe":[{"pmid":"27668156","year":"2016","title":"Cicletanine-induced hyponatremia and hypokalemia in kidney transplant patients.","finding":"","journal":"Kidney research and clinical practice","studyType":"Clinical Study"},{"pmid":"26000442","year":"2015","title":"Blood pressure-lowering efficacy of loop diuretics for primary hypertension.","finding":"","journal":"The Cochrane database of systematic reviews","studyType":"Clinical Study"},{"pmid":"23639812","year":"2013","title":"Cicletanine stimulates eNOS phosphorylation and NO production via Akt and MAP kinase/Erk signaling in sinusoidal endothelial cells.","finding":"","journal":"American journal of physiology. Gastrointestinal and liver physiology","studyType":"Clinical Study"},{"pmid":"22895937","year":"2012","title":"Blood pressure lowering efficacy of loop diuretics for primary hypertension.","finding":"","journal":"The Cochrane database of systematic reviews","studyType":"Clinical Study"},{"pmid":"22622233","year":"2012","title":"Beneficial cardiac effects of cicletanine in conscious rabbits with metabolic syndrome.","finding":"","journal":"Journal of cardiovascular pharmacology","studyType":"Clinical Study"}],"tags":[{"label":"cicletanine","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"C03BX03","category":"atc"},{"label":"Active","category":"status"},{"label":"Anti-Arrhythmia Agents","category":"pharmacology"},{"label":"Antihypertensive Agents","category":"pharmacology"},{"label":"Cardiovascular Agents","category":"pharmacology"},{"label":"Diuretics","category":"pharmacology"},{"label":"Natriuretic Agents","category":"pharmacology"}],"phase":"discontinued","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"cicletanide","offLabel":[],"synonyms":["cicletanine","cicletanide","cycletanide","(+/-)-Cicletanine"],"timeline":[],"approvals":[],"brandName":"Cicletanide","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"cicletanine","explanation":"Imagine your body's cells have a complex communication system. Cicletanine is thought to interfere with this system in a way that helps to treat certain conditions, although the exact details of how it does this are not yet fully understood.","oneSentence":"Cicletanine works by interacting with a specific cellular pathway to produce its therapeutic effects.","technicalDetail":"Cicletanine's mechanism of action is not well-characterized, but it is believed to involve modulation of ion channels or other cellular receptors, leading to changes in cellular signaling and potentially therapeutic effects."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/634","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=CICLETANINE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CICLETANINE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T09:36:52.028879","biosimilars":[],"competitors":[],"genericName":"cicletanine","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT02709031","phase":"PHASE1,PHASE2","title":"Cicletanine in Hypertension With Diabetes: Added Magnesium Preserves Potassium and Sodium","status":"UNKNOWN","sponsor":"Navitas Pharma","startDate":"2022-06","conditions":["Arterial Hypertension","Diabetes","Hypokalemia","Hyponatremia"],"enrollment":24,"completionDate":"2024-09"},{"nctId":"NCT00832507","phase":"PHASE2","title":"Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2009-01","conditions":["Pulmonary Arterial Hypertension"],"enrollment":162,"completionDate":"2012-03"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"004193","UNII":"CHG7QC509W","CHEBI":"CHEBI:135078","INN_ID":"5596","RXNORM":"21914","UMLSCUI":"C0056686","ChEMBL_ID":"CHEMBL191886","KEGG_DRUG":"D03487","DRUGBANK_ID":"DB12766","PUBCHEM_CID":"54910","SNOMEDCT_US":"735156005","MESH_SUPPLEMENTAL_RECORD_UI":"C038068"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":197,"therapeuticAreas":["Other"],"atcClassification":{"source":"DrugCentral","atcCode":"C03BX03","allCodes":["C03BX03"]},"biosimilarFilings":[],"recentPublications":[{"date":"2016 Sep","pmid":"27668156","title":"Cicletanine-induced hyponatremia and hypokalemia in kidney transplant patients.","journal":"Kidney research and clinical practice"},{"date":"2015 May 22","pmid":"26000442","title":"Blood pressure-lowering efficacy of loop diuretics for primary hypertension.","journal":"The Cochrane database of systematic reviews"},{"date":"2013 Jul 15","pmid":"23639812","title":"Cicletanine stimulates eNOS phosphorylation and NO production via Akt and MAP kinase/Erk signaling in sinusoidal endothelial cells.","journal":"American journal of physiology. Gastrointestinal and liver physiology"},{"date":"2012 Aug 15","pmid":"22895937","title":"Blood pressure lowering efficacy of loop diuretics for primary hypertension.","journal":"The Cochrane database of systematic reviews"},{"date":"2012 Aug","pmid":"22622233","title":"Beneficial cardiac effects of cicletanine in conscious rabbits with metabolic syndrome.","journal":"Journal of cardiovascular pharmacology"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"discontinued","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cicletanine, a small molecule drug in the cicletanine class, is a compound with unknown target and mechanism of action. Its commercial status is unclear, and it is not approved by the FDA for any indications. As a result, there is limited information available on its pharmacokinetic properties, such as half-life and bioavailability. Further research is needed to determine its potential therapeutic applications and safety profile. The compound's development history is also unclear, with unknown original developers and current owners.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}